fbpx

Drug due to be rejected by NICE for use on the NHS for MS

Drug due to be rejected by NICE for use on the NHS for MS Published: 21 December 2021 Famprya (fampridine) is set to be rejected by The National Institute for Health and Care Excellence (NICE) in England for use on the NHS for people with multiple sclerosis (MS). NICE will
Read More

New clues for predicting rare brain infection linked to MS drug

New clues for predicting rare brain infection linked to MS drugPublished: 05 October 2021 A new study has found that John Cunningham virus mutations may be an early predictor for brain infection in people receiving Tysabri for multiple sclerosis (MS).  Tysabri works by preventing immune cells from entering the brain
Read More

This MS drug increases risk of hospitalisation

This MS drug increases risk of hospitalisation Published: 27 August 2021 A new study has found that Ocrevus (ocrelizumab) slows disability progression and reduces relapse risk in people with multiple sclerosis (MS) but is also associated with higher hospitalisation risk in older people.  Most of the hospitalisations were from urinary
Read More

New drug approved in Scotland for MS

New drug approved in Scotland for MSPublished: 13 July 2021 People living in Scotland can now be prescribed Kesimpta (ofatumumab),  The Scottish Medicines Consortium (SMC) has recommended. It will be available for those who have relapsing-remitting multiple sclerosis (MS) who are experiencing relapses or have disease activity visible with an
Read More